Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Does Orthostatic Hypotension Affect Cognition in Parkinson Disease? A Longitudinal Pilot Study
Neuromuscular and Clinical Neurophysiology (EMG)
P5 - Poster Session 5 (8:00 AM-9:00 AM)
1-007

To determine whether orthostatic hypotension (OH) impacts cognition in Parkinson disease (PD) over time as measured by Montreal Cognitive Assessment (MoCA), and whether cognition differs between symptomatic (sOH) and asymptomatic OH (aOH) patients.

Autonomic nervous system dysfunction causing OH affects up to half of PD patients1. OH can lead to many symptoms including cognitive disturbances2-4. OH can also be asymptomatic, and may cause transient cognitive decline without overt symptoms5-8. Limited studies suggest that aOH and sOH PD patients have similar ambulatory and functional capacity, falls, and healthcare utilization9, 10, but it remains unknown whether cognition differs between these groups. A better understanding of the association between OH and cognition is needed to guide therapeutic decision-making.  

Baseline and one follow-up visit data (mean follow-up duration= 4.2 years) was retrospectively obtained from our IRB-approved database.18 OH- and 18 OH+ (9 aOH, 9 sOH) PD patients matched for age, sex, education, disease duration, Hoehn and Yahr stage, and follow-up interval were identified. MoCA scores at baseline and final follow-up visits were compared between OH- and OH+, and sOH and aOH groups using repeated measures analysis of variance.  

MoCA scores increased at follow-up for OH- patients (baseline 24.8, follow-up 26.1), but decreased for OH+ patients (25.1, 23.5), showing that OH had a deteriorating impact on MoCA over time (p=0.025). Within the OH+ group, disease duration was longer in sOH compared to aOH (p=0.004). There was no difference in MoCA change between sOH and aOH (p=0.51), and no significant group and time interaction (p=0.56). There were no demographic differences between sOH and aOH groups.

Presence of OH was associated with clinically and statistically significant cognitive decline over time, independent of orthostatic symptoms. Larger studies are warranted to clarify how OH contributes to longitudinal cognitive decline, and whether treating OH has beneficial effects on cognition.

Authors/Disclosures
Katherine Longardner, MD (UCSD MEDICAL CENTER)
PRESENTER
Dr. Longardner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boston Scientific. Dr. Longardner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. An immediate family member of Dr. Longardner has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Boston Scientific. An immediate family member of Dr. Longardner has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Trisalus. An immediate family member of Dr. Longardner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AstraZenica. An immediate family member of Dr. Longardner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sirtex. An immediate family member of Dr. Longardner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Society of Interventional Oncology. An immediate family member of Dr. Longardner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for France Foundation. An immediate family member of Dr. Longardner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Varian. Dr. Longardner has received research support from NIH.
Ece Bayram, MD, PhD The institution of Dr. Bayram has received research support from National Institute on Aging (K99AG073453). The institution of Dr. Bayram has received research support from Lewy Body Dementia Association. The institution of Dr. Bayram has received research support from National Institute of Neurological Disorders and Stroke.
Irene Litvan, MD, FÂé¶¹´«Ã½Ó³»­ (UC San Diego Parkinson and Other Movement Disorder Center) Dr. Litvan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aprinoia. Dr. Litvan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Litvan has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Frontiers in Neurology. Dr. Litvan has received personal compensation in the range of $50,000-$99,999 for serving as a Chief Editor with Frontiers in Neurology.